1)Sacco RL, et al:Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death;Subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis 22:4-12, 2006
2)Hart RG, et al:Embolic strokes of undetermined source:the case for a new clinical construct. Lancet Neurol 13:429-438, 2014
3)Hart RG, et al:Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 378:2191-2201, 2018
4)Tsivgoulis G, et al:Embolic strokes of undetermined source:theoretical construct or useful clinical tool?. Ther Adv Neurol Disord 12:1756286419851381, 2019
5)S Poli, et al:Apixaban for treatment of embolic stroke of undetermined source(ATTICUS)randomized trial;Update of patient characteristics and study timeline after interim analysis. Eur Heart J 42(Issue Supplement_1):ehab724.2070, 2021
6)日本脳卒中学会 脳卒中ガイドライン委員会(編):脳卒中治療ガイドライン2021,協和企画,2021
7)Geisler T, et al:Apixaban for treatment of embolic stroke of undetermined source(ATTICUS randomized trial);Rationale and study design. Int J Stroke 12:985-990, 2017
8)日本脳卒中学会 脳卒中医療向上・社会保険委員会 潜因性脳梗塞患者診断の手引き作成部会:植込み型心電図記録計の適応となり得る潜因性脳梗塞患者の診断の手引き https://www.jsts.gr.jp/img/tebiki_noukousoku.pdf(2022年11月閲覧)
9)Sanna T, et al:Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370:2478-2486, 2014
10)Triantafyllou S, et al:Implantable cardiac monitoring in the secondary prevention of cryptogenic stroke. Ann Neurol 88:946-955, 2020